GenFleet Therapeutics's GFH312 is a small molecule inhibitor of receptor-interacting serine/threonine protein-1(RIP1) kinase, a key regulator of the TNF- downstream. GenFleet is the first Chinese company that moves RIPK1 inhibitor development into clinical stage.
A Phase Ib/II trial will analyse GFH018 in combination with a PD-1 inhibitor for advanced solid tumour patients. The other study is a Phase II trial of GFH018, a PD-1 inhibitor along with immunochemotherapy and radiotherapy to treat locally advanced and unresectable non-small cell lung cancer (NSCLC) patients.
In retrospect, China’s rise in biopharma may seem inevitable: If nothing else, the sheer size of the population spells a boon for both drug research and sales. But the world didn’t always see it that way.
It's been a big year for the long undruggable target. The first inhibitor — Lumakras sotorasib from Amgen Inc. — reached the market in May under the accelerated approval pathway for non-small cell lung cancer (NSCLC), and Amgen and Mirati both revealed strong proof of concept in colorectal cancer at this month’s European Society for Clinical Oncology (ESMO) Congress.
Shanghai-based GenFleet has been developing GFH925 as a treatment for non-small cell lung cancer and other solid tumors.
Chinese pharma companies Innovent and GenFleet have entered into an exclusive licensing agreement for developing and commercializing GenFleet’s GFH925, the company’s lead KRAS G12C candidate in the China, Hong Kong, Macau and Taiwan markets.
GenFleet Therapeutics raised $58 million in series B funding to bankroll clinical trials of its pipeline, including a small molecule for liver cancer.
For the last decade or so, many of the more eye-catching Chinese biotech startups share two defining attributes